NAL Pharmaceuticals Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘NAL Pharmaceuticals Ltd. – Product Pipeline Review – 2016’, provides an overview of the NAL Pharmaceuticals Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by NAL Pharmaceuticals Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of NAL Pharmaceuticals Ltd.

The report provides overview of NAL Pharmaceuticals Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses NAL Pharmaceuticals Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features NAL Pharmaceuticals Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate NAL Pharmaceuticals Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for NAL Pharmaceuticals Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding NAL Pharmaceuticals Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

NAL Pharmaceuticals Ltd. Snapshot 6

NAL Pharmaceuticals Ltd. Overview 6

Key Information 6

Key Facts 6

NAL Pharmaceuticals Ltd. - Research and Development Overview 7

Key Therapeutic Areas 7

NAL Pharmaceuticals Ltd. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

NAL Pharmaceuticals Ltd. - Pipeline Products Glance 12

NAL Pharmaceuticals Ltd. - Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

NAL Pharmaceuticals Ltd. - Unknown Stage Pipeline Products 14

Unknown Products/Combination Treatment Modalities 14

NAL Pharmaceuticals Ltd. - Drug Profiles 15

pegfilgrastim 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

montelukast sodium 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

diclofenac sodium 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

donepezil hydrochloride 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

donepezil hydrochloride Patch 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

formoterol fumarate 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

galantamine hydrobromide 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

indomethacin 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ketoprofen 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

levocetirizine dihydrochloride 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

NAL-3216 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

NAL-3221 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

NAL-3223 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

nicotine bitartrate 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

rizatriptan benzoate 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

sildenafil citrate 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

sufentanil citrate 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

tadalafil 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

tulobuterol 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

NAL Pharmaceuticals Ltd. - Pipeline Analysis 34

NAL Pharmaceuticals Ltd. - Pipeline Products by Target 34

NAL Pharmaceuticals Ltd. - Pipeline Products by Route of Administration 36

NAL Pharmaceuticals Ltd. - Pipeline Products by Molecule Type 37

NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action 38

NAL Pharmaceuticals Ltd. - Dormant Projects 39

NAL Pharmaceuticals Ltd. - Locations And Subsidiaries 40

Head Office 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

NAL Pharmaceuticals Ltd., Key Information 6

NAL Pharmaceuticals Ltd., Key Facts 6

NAL Pharmaceuticals Ltd. – Pipeline by Indication, 2016 8

NAL Pharmaceuticals Ltd. – Pipeline by Stage of Development, 2016 10

NAL Pharmaceuticals Ltd. – Monotherapy Products in Pipeline, 2016 11

NAL Pharmaceuticals Ltd. – Preclinical, 2016 12

NAL Pharmaceuticals Ltd. – Discovery, 2016 13

NAL Pharmaceuticals Ltd. – Unknown, 2016 14

NAL Pharmaceuticals Ltd. – Pipeline by Target, 2016 35

NAL Pharmaceuticals Ltd. – Pipeline by Route of Administration, 2016 36

NAL Pharmaceuticals Ltd. – Pipeline by Molecule Type, 2016 37

NAL Pharmaceuticals Ltd. – Pipeline Products by Mechanism of Action, 2016 38

NAL Pharmaceuticals Ltd. – Dormant Developmental Projects,2016 39

List of Figures

List of Figures

NAL Pharmaceuticals Ltd. – Pipeline by Top 10 Indication, 2016 8

NAL Pharmaceuticals Ltd. – Pipeline by Stage of Development, 2016 10

NAL Pharmaceuticals Ltd. – Monotherapy Products in Pipeline, 2016 11

NAL Pharmaceuticals Ltd. – Pipeline by Top 10 Target, 2016 34

NAL Pharmaceuticals Ltd. – Pipeline by Top 10 Route of Administration, 2016 36

NAL Pharmaceuticals Ltd. – Pipeline by Molecule Type, 2016 37

NAL Pharmaceuticals Ltd. – Pipeline Products by Top 10 Mechanism of Action, 2016 38

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports